Advice

following a resubmission:

brodalumab (Kyntheum®) is accepted for restricted use within NHSScotland.

Indication under review: for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.

SMC restriction: for patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.

Brodalumab was superior to placebo and to an alternative interleukin inhibitor at improving symptoms in adults with moderate to severe plaque psoriasis.

This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost- effectiveness of brodalumab. It is contingent upon the continuing availability of the Patient Access Scheme in NHSScotland or a list price that is equivalent or lower.

Download detailed advice278KB (PDF)

Download

Medicine details

Medicine name:
brodalumab (Kyntheum)
SMC ID:
1283/17
Indication:
For the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy.
Pharmaceutical company
LEO Pharmaceuticals
BNF chapter
Skin
Submission type
Resubmission
Status
Restricted
Date advice published:
07 May 2018